Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Weißdorn (Hawthorn extract) is a botanical extract derived from the leaves, flowers, and berries of *Crataegus* species (primarily *Crataegus monogyna* and *Crataegus laevigata*). It is widely used in European phytotherapy as a cardiotonic agent for the treatment of mild heart failure (NYHA class II) and orthostatic circulatory disorders. The extract contains a complex mixture of bioactive compounds, including oligomeric procyanidins (OPCs) and flavonoids (such as vitexin and hyperoside). Weißdorn exerts its therapeutic effects through multiple mechanisms, including the inhibition of the sarcolemmal Na+/K+-ATPase pump (which increases intracellular calcium and enhances myocardial contractility), the inhibition of phosphodiesterase 3 (PDE3), and the activation of endothelial nitric oxide synthase (eNOS), leading to vasodilation and improved coronary blood flow. It is marketed in various formulations, both as a mono-preparation and in combination with other active ingredients like D-camphor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Weißdorn.